Afya (NASDAQ:AFYA) Given "Hold (C)" Rating at Weiss Ratings

Key Points

• Afya's stock has been rated as "Hold (C)" by Weiss Ratings, with several analysts providing mixed ratings, including upgrades and downgrades.
• Shares of Afya traded down 0.9% to $14.91, with a 12-month high of $19.90 and a consensus target price of $18.20 from analysts.
• Institutional investors own approximately 88.02% of Afya's stock, indicating strong institutional interest in the company.

Afya (NASDAQ:AFYA - Get Free Report)'s stock had its "hold (c)" rating reissued by equities researchers at Weiss Ratings in a research note issued to investors on Friday,Weiss Ratings reports.

Several other equities research analysts have also issued reports on the stock. Wall Street Zen lowered shares of Afya from a "strong-buy" rating to a "buy" rating in a report on Saturday, October 18th. Morgan Stanley set a $17.50 price objective on shares of Afya and gave the company an "overweight" rating in a research note on Wednesday, August 6th. Zacks Research upgraded shares of Afya to a "hold" rating in a research note on Friday, August 8th. UBS Group raised shares of Afya from a "neutral" rating to a "buy" rating and cut their target price for the company from $19.50 to $19.00 in a report on Monday, September 8th. Finally, JPMorgan Chase & Co. raised shares of Afya from a "neutral" rating to an "overweight" rating and lifted their target price for the company from $23.50 to $24.50 in a report on Monday, September 8th. Three research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $18.20.

Afya Trading Down 0.9%

Shares of AFYA traded down $0.14 during trading hours on Friday, reaching $14.91. 43,347 shares of the company traded hands, compared to its average volume of 108,429. The company has a quick ratio of 0.94, a current ratio of 0.94 and a debt-to-equity ratio of 0.22. The company has a market capitalization of $1.40 billion, a price-to-earnings ratio of 11.29, a price-to-earnings-growth ratio of 0.45 and a beta of 0.61. Afya has a 12 month low of $13.47 and a 12 month high of $19.90. The company's fifty day moving average price is $15.28 and its two-hundred day moving average price is $16.58.

Hedge Funds Weigh In On Afya

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Cerity Partners LLC bought a new stake in shares of Afya in the 1st quarter worth approximately $476,000. Nuveen LLC acquired a new stake in shares of Afya in the 1st quarter valued at $226,000. Wealthedge Investment Advisors LLC acquired a new position in Afya during the 1st quarter worth about $230,000. Doma Perpetual Capital Management LLC lifted its holdings in Afya by 4.4% during the 1st quarter. Doma Perpetual Capital Management LLC now owns 592,220 shares of the company's stock worth $10,619,000 after buying an additional 25,111 shares during the period. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Afya by 167.3% in the first quarter. Goldman Sachs Group Inc. now owns 45,093 shares of the company's stock valued at $809,000 after acquiring an additional 28,226 shares in the last quarter. 88.02% of the stock is owned by institutional investors and hedge funds.

About Afya

Afya Limited, through its subsidiaries, operates as a medical education group in Brazil. The company operates through three segments: Undergrad, Continuing Education, and Digital Services. It offers educational products and services, including medical schools, medical residency preparatory courses, graduate courses, and other programs to lifelong medical learners enrolled across its distribution network, as well as to third-party medical schools.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.